Cancer Immunotherapeutics In the News

colorectal cancer screening

People with colon and rectal tumors prone to “immune overdrive” don’t do well if they concurrently have an immune-suppressive tumor microenvironment, City of Hope researchers say.


News Image

People with colon and rectal tumors prone to “immune overdrive” don’t do well if they concurrently have an immune-suppressive tumor microenvironment, City of Hope researchers say.

HPV cells

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.


Breakthroughs - prostate cancer clinical trial

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.


Saul Priceman | City of Hope

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.


News Image

Saul Priceman, Ph.D., City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received an award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

News Image

City of Hope researchers found that “turning off” the BCL6 protein and using the small molecule ABT-199 eliminated drug resistance in mouse models that had a subtype of B cell acute lymphoblastic leukemia.

News Image

City of Hope is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that, if successful, eventually could transform treatment of the usually fatal disease into an outpatient procedure.

Caitlin Buchanon Small | City of Hope

Diagnosed with a rare, fast-growing blood cancer and ineligible for a lifesaving stem cell transplant after failing chemotherapy, treatment with a breakthrough CAR T drug called Yescarta was Caitlin Buchanan's best hope for survival.


Nadia Carlesso, M.D. - Profile Photo

Inspiration came early to Nadia Carlesso, M.D., Ph.D., associate director of basic research in the Gehr Family Center for Leukemia Research at City of Hope.


Radiotherapy for Breast Cancer at City of Hope

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.


News Image

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.

Warner-Susanne

At City of Hope since 2015, Susanne Warner, M.D., regularly draws notice and praise for her surgical skills, her research chops and especially her Texas-sized optimism.


Tyler Routh | City of Hope

Tyler Routh is one of 13 leukemia patients who had a remarkable recovery after participating in Dr. Samer Khaled’s CAR T trial.


li-daneng-300x300

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


News Image

Study results will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

News Image

City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.

test tubes

City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.


AML | City of Hope

City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.


Blood Cancer | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.


li-daneng-300x300

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.


News Image

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.

Christiane Querfeld, M.D., Ph.D.

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.